Advertisement
CLGN vs SPRO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLGN is a Hold and SPRO is a StrongBuy.
CLGN's Stochastic Oscillator descends into oversold zone
The Stochastic Oscillator for CLGN moved into oversold territory on October 23, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on CLGN as a result. In 70 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for CLGN just turned positive on October 08, 2026. Looking at past instances where CLGN's MACD turned positive, the stock continued to rise in 32 of 44 cases over the following month. The odds of a continued upward trend are 73%.
The 50-day moving average for CLGN moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +7.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLGN advanced for three days, in 168 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day moving average for CLGN crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.416) is normal, around the industry mean (3.035). P/E Ratio (-3.519) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (11.494) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CLGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SPRO sees its Stochastic Oscillator ascends from oversold territory
On October 20, 2026, the Stochastic Oscillator for SPRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 55 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +10.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 151 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for SPRO moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 37 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SPRO broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SPRO entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.462) is normal, around the industry mean (3.035). P/E Ratio (7.929) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CLGN | SPRO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 34 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 48 | |
PRICE GROWTH RATING 1..100 | 63 | 80 | |
P/E GROWTH RATING 1..100 | 59 | 89 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLGN's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for SPRO (79) in the Pharmaceuticals Major industry. This means that CLGN’s stock grew somewhat faster than SPRO’s over the last 12 months.
CLGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that CLGN’s stock grew similarly to SPRO’s over the last 12 months.
SPRO's SMR Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for CLGN (99) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CLGN’s over the last 12 months.
CLGN's Price Growth Rating (63) in the Biotechnology industry is in the same range as SPRO (80) in the Pharmaceuticals Major industry. This means that CLGN’s stock grew similarly to SPRO’s over the last 12 months.
CLGN's P/E Growth Rating (59) in the Biotechnology industry is in the same range as SPRO (89) in the Pharmaceuticals Major industry. This means that CLGN’s stock grew similarly to SPRO’s over the last 12 months.
| CLGN | SPRO | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 89% |
| Stochastic ODDS (%) | 3 days ago 83% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 80% | 3 days ago 87% |
| MACD ODDS (%) | 3 days ago 73% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 78% | 3 days ago 74% |
| TrendMonth ODDS (%) | 3 days ago 89% | 3 days ago 87% |
| Advances ODDS (%) | 6 days ago 81% | 6 days ago 73% |
| Declines ODDS (%) | 4 days ago 90% | 3 days ago 88% |
| BollingerBands ODDS (%) | N/A | 4 days ago 89% |
| Aroon ODDS (%) | N/A | 3 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLGN’s FA Score shows that 0 FA rating(s) are green while SPRO’s FA Score has 0 green FA rating(s).
- CLGN’s FA Score: 0 green, 5 red.
- SPRO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLGN’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 2 bullish TA indicator(s).
- CLGN’s TA Score: 5 bullish, 2 bearish.
- SPRO’s TA Score: 2 bullish, 8 bearish.
Price Growth
CLGN (@Biotechnology) experienced а +3.10% price change this week, while SPRO (@Biotechnology) price change was +0.91% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
CLGN is expected to report earnings on Nov 25, 2026.
SPRO is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CLGN and
Correlation & Price change
A.I.dvisor tells us that CLGN and CLLS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLGN and CLLS's prices will move in lockstep.
| Ticker / NAME | Correlation To CLGN | 1D Price Change % | ||
|---|---|---|---|---|
| CLGN | 100% | +0.27% | ||
| CLLS - CLGN | 33% Poorly correlated | +0.51% | ||
| SPRO - CLGN | 30% Poorly correlated | -1.77% | ||
| ALZN - CLGN | 26% Poorly correlated | N/A | ||
| VOR - CLGN | 25% Poorly correlated | -3.59% | ||
| ACET - CLGN | 24% Poorly correlated | -6.78% | ||
More | ||||
SPRO and
Correlation & Price change
A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then CCXI could also see price increases.
| Ticker / NAME | Correlation To SPRO | 1D Price Change % | ||
|---|---|---|---|---|
| SPRO | 100% | -1.77% | ||
| CCXI - SPRO | 48% Loosely correlated | -0.05% | ||
| ASBP - SPRO | 42% Loosely correlated | -2.56% | ||
| VYGR - SPRO | 34% Loosely correlated | -6.45% | ||
| JAGX - SPRO | 34% Loosely correlated | -5.12% | ||
| VKTX - SPRO | 32% Poorly correlated | -5.54% | ||
More | ||||